Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $30,989 | $25,478 | $15,345 | $1,718 |
| % Growth | 21.6% | 66% | 793.2% | – |
| Cost of Goods Sold | $1,934 | $340 | $1,478 | $50,506 |
| Gross Profit | $29,055 | $25,138 | $13,867 | -$48,788 |
| % Margin | 93.8% | 98.7% | 90.4% | -2,839.8% |
| R&D Expenses | $99,388 | $79,912 | $73,520 | $51,106 |
| G&A Expenses | $0 | $0 | $37,278 | $18,549 |
| SG&A Expenses | $61,152 | $56,845 | $37,278 | $18,549 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1,169 | $657 | -$37 |
| Operating Expenses | $160,540 | $137,926 | $110,798 | $69,655 |
| Operating Income | -$131,485 | -$112,788 | -$96,931 | -$67,937 |
| % Margin | -424.3% | -442.7% | -631.7% | -3,954.4% |
| Other Income/Exp. Net | -$11,458 | $96,361 | -$1,845 | $462 |
| Pre-Tax Income | -$142,943 | -$16,427 | -$98,776 | -$67,475 |
| Tax Expense | -$1,538 | $3,389 | $0 | $0 |
| Net Income | -$141,405 | -$19,816 | -$101,660 | -$66,642 |
| % Margin | -456.3% | -77.8% | -662.5% | -3,879% |
| EPS | -2.63 | -0.51 | -2.77 | -2.44 |
| % Growth | -415.7% | 81.6% | -13.5% | – |
| EPS Diluted | -2.63 | -0.51 | -2.77 | -2.44 |
| Weighted Avg Shares Out | 53,747 | 39,073 | 36,697 | 27,270 |
| Weighted Avg Shares Out Dil | 53,747 | 39,073 | 36,697 | 27,270 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,113 | $2,354 | $80 | $499 |
| Interest Expense | $16,895 | $10,672 | $2,582 | $0 |
| Depreciation & Amortization | $551 | $669 | $667 | $598 |
| EBITDA | -$125,497 | -$5,086 | -$95,527 | -$66,877 |
| % Margin | -405% | -20% | -622.5% | -3,892.7% |